Search Results for “AI” – Page 38 – media

US WorldMeds’ Iwilfin bags FDA nod as 1st oral maintenance treatment for high-risk neuroblastoma

While existing neuroblastoma treatments can help patients achieve remission, sustaining that remission has proven tricky. But now, patients and doctors have a new oral option. This week, the U.S. FDA approved US WorldMeds’ (USWM) Iwilfin—also known as eflornithine—as a new oral maintenance therapy for high-risk neuroblastoma. The drug, cleared in 192 mg tablets, is indicated to cut the risk of relapse in kids and adults with high-risk neuroblastoma who’ve had at least a partial response to prior multiagent, multimodality treatment, USWM said in a press release. Between 700 and 800 cases of neuroblastoma are diagnosed in the U.S. each year, according to the American Cancer Society. Ninety percent of diagnoses occur before a patient is 5 years old and more than 50% of neuroblastoma cases are classified as high-risk. Approximately half of children with high-risk neuroblastoma don’t live more than five years past their diagnosis, USWM added. Avoiding relapse is ...
- Source: drugdu
- 89
- December 16, 2023
Sino Biopharm’ S&P ESG Score Gains Another Boost, Stays in Top 9% Globally

Recently, S&P Global Corporate Sustainability Assessment (CSA) has been releasing the results of 2023 Environmental, Social and Governance (ESG) scores. Sino Biopharm (HK.1177) has achieved a second consecutive year of improved ratings. This year, the Group’s rating steadily improved to 55 points, up 10 points from the previous year, and ranked in the top 9% globally for the second consecutive year. The S&P Global Corporate Sustainability Assessment is one of the world’s largest annual assessments of corporate sustainability practices, which comprehensively reflects the level of ESG management and disclosure of companies through quantitative scoring of companies’ ESG management and performance, and is an important basis for investment decisions and data analysis by global investors. 2023, approximately 350 companies in the pharmaceutical industry around the world were invited to participate in the assessment. For two consecutive years, the company has outperformed 91% of its global peers, representing the organization’s high recognition ...
- Source: drugdu
- 104
- December 15, 2023
After leak of neurotoxin, Sanofi plant in France is under scrutiny again

A Sanofi manufacturing facility in France, which was temporarily closed five years ago for emitting dangerous emissions, is under the microscope again after a recent leak caused the release of the same neurotoxin, bromopropane. The plant, which produces epilepsy drug Depakine (sodium valproate), released 75 times the allowable amount of bromopropane in mid-November, according to a report in the French news outlet Le Monde. The facility, located in Mourenx, stopped production “immediately” after noting “inconsistent measurements” of bromopropane emissions, according to a Sanofi spokesperson. “We quickly identified that this isolated and very brief event was linked to the degradation of the treatment unit’s activated carbons following the bad weather and heavy rains that had affected the region in the preceding days,” Sanofi said. “The coals were replaced and bromopropane emissions returned to normal, enabling production to resume after approval from the authorities.” Bromopropane—which is used in the production of Depakine—is ...
- Source: drugdu
- 104
- December 14, 2023
Medtronic expands AI endoscopy partnership with Cosmo

Dive Brief Medtronic will pay Cosmo Intelligent Medical Devices $100 million upfront to expand a partnership that makes Medtronic the exclusive global distributor of Cosmo’s GI Genius platform. GI Genius received de novo clearance in 2021 and uses machine learning to flag regions of interest during a colonoscopy, helping physicians detect lesions, such as polyps or suspected tumors. In addition, Medtronic said it would pay a double-digit royalty on net sales and another $100 million in milestone payments that it expects the partnership to reach by the end of 2024. Dive Insight Medtronic first started working with Cosmo Intelligent Medical Devices, a subsidiary of Cosmo Pharmaceuticals, in 2019. When the Food and Drug Administration cleared GI Genius a few years later, the agency said it was the first device that used machine learning to help clinicians detect lesions in the colon. Now, Cosmo and Medtronic are expanding their partnership, including ...
- Source: drugdu
- 99
- December 13, 2023
Large language models enhance differential diagnosis, paving the way for AI-assisted medical decision-making

A recent study published in the ArXiv preprint* server discusses the optimization of large language models (LLMs) for accurate differential diagnosis (DDx). Background Accurate diagnosis is the first step in effective medical care. It has been perceived that artificial intelligence (AI)-based models can be used to assist clinicians for accurate diagnosis of a disease. The real-world diagnostic process involves an interactive and iterative process with rational reasoning about a DDx. A physician weighs different diagnostic possibilities based on varied clinical information procured from advanced diagnostic procedures. Deep learning has been applied to the generation of DDx in ophthalmology, dermatology, and radiology. Due to the absence of interactive capabilities, deep learning models cannot assist patients with diagnosis through fluent communication in their native language. This interactive shortcoming can be overcome with the development of LLMs, which can be used to design effective tools for DDx. LLMs are trained using a massive ...
- Source: drugdu
- 217
- December 9, 2023
What Excites One Mayo Clinic Radiologist About AI in Her Field

Dr. Wendaline VanBuren, a radiology chair at Mayo Clinic, thinks that AI is in the beginning stages of improving radiologists’ workflows. Some of the most developed radiology AI research projects at Mayo center on image segmentation and 3D printing, she said. In the future, she’s excited to see more tools that aid radiologists in triage and lesion measurement. By KATIE ADAMS Radiology, like most physician specialties, is dealing with a labor shortage driven by burnout and an aging workforce. AI is often heralded as something that can help solve these workforce problems, but a lot of AI deployment in radiology is still in its iterative phase, said Dr. Wendaline VanBuren, chair of the gynecological imaging section within the division of abdominal radiology at Mayo Clinic. Dr. VanBuren made this remark last week during an interview at RSNA 2023, the annual radiology and medical imaging conference in Chicago. While AI still ...
- Source: drugdu
- 104
- December 8, 2023
Daiichi Sankyo scores $182M from Novartis settlement in long-running patent case

After years of back and forth with Daiichi Sankyo over cancer drug patent claims, Novartis has thrown in the towel with a $182 million settlement. The case stems back to 2017 and has its roots in Novartis’ Tafinlar, a melanoma therapy that the company acquired from GSK after a 2015 asset swap. Daiichi’s former subsidiary Plexxikon, which makes melanoma treatment Zelboraf, alleged that GSK scientists only gathered the knowledge necessary to develop the rival drug after consulting with Plexxikon for talks about a partnership that never came to fruition. Plexxikon’s patents date back to 2005, while GSK filed its first patent application on the drug in 2008, Plexxikon said. In 2021, a Northern California jury ruled in favor of Plexxikon, determining that Novartis stepped on two of the Daiichi subsidiary’s patents. Novartis was ordered to pay Daiichi’s subsidiary 9% royalty payments on future Tafinlar sales until certain Zelboraf patents expire ...
- Source: drugdu
- 109
- December 8, 2023
AstraZeneca and generative AI company Absci enter $247m oncology partnership

AstraZeneca (AZ) and Absci have entered into a collaboration agreement worth up to $247m to develop an artificial intelligence (AI)-designed antibody drug for a specified oncology target. The partnership will combine AZ’s capabilities in oncology research and development with Absci’s Integrated Drug Creation platform, which the generative AI company says “unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimising multiple drug characteristics important to both development and therapeutic benefit”. The agreement includes an upfront commitment from AZ as well as research and development funding, milestone payments and royalties on product sales. Puja Sapra, senior vice president of biologics engineering and oncology targeted delivery at AZ, said: “This collaboration is an exciting opportunity to utilise Absci’s de novo AI antibody creation platform to design a potential new antibody therapy in oncology.” Absci outlines that its approach “overcomes the limits of traditional drug discovery”. ...
- Source: drugdu
- 124
- December 8, 2023
Eli Lilly Announces Availability of Obesity Drug Zepbound at US Pharmacies

Pharmaceutical Executive Editorial Staff Patients with obesity are now able to access Zepbound (tirzepatide) with a prescription at retail and mail-order pharmacies across six dose strengths. Eli Lilly and Company announced today that its obesity treatment Zepbound (tirzepatide) is now commercially available at pharmacies in the United States.1 Last month, the FDA approved Zepbound injection as the first and only approved treatment for obesity that activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) hormone receptors.2 Image credit: Kurhan | stock.adobe.com Patients with obesity are now able to access Zepbound with a prescription at retail and mail-order pharmacies across six dose strengths—2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg. “Today opens another chapter for adults living with obesity who have been looking for a new treatment option like Zepbound,” said Rhonda Pacheco, group vice president, Lilly Diabetes and Obesity, US, in a press release.1 The ...
- Source: drugdu
- 185
- December 7, 2023
Aledade, Anthem Form New Value-Based Medicaid Partnership for Virginians

Anthem Blue Cross and Blue Shield in Virginia has partnered with Aledade, a network of independent primary care practices, to improve access to value-based primary care for Medicaid members, the companies announced last week. Bethesda, Maryland-based Aledade helps independent practices, health centers and clinics engage in value-based care through data insights, policy expertise and contracting support. It works with more than 1,500 practices and community health centers across 46 states and the District of Columbia. Through the partnership, Anthem’s Medicaid members will have better access to primary and preventive care, including health screenings. Aledade and Anthem began working together last year with the insurer’s Medicare Advantage and commercially insured members. The partnership enables Aledade to bring value-based care — in which clinicians are paid based on the quality of care they deliver versus the volume of care they provide — to more than 80 practices, 15 health centers and 25 ...
- Source: drugdu
- 97
- December 6, 2023

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.